Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia
Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about the...
Gespeichert in:
Veröffentlicht in: | American journal of respiratory and critical care medicine 2008-01, Vol.177 (1), p.66-74 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 74 |
---|---|
container_issue | 1 |
container_start_page | 66 |
container_title | American journal of respiratory and critical care medicine |
container_volume | 177 |
creator | Huang, Steven K Wettlaufer, Scott H Hogaboam, Cory M Flaherty, Kevin R Martinez, Fernando J Myers, Jeffrey L Colby, Thomas V Travis, William D Toews, Galen B Peters-Golden, Marc |
description | Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator.
To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts.
Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined.
Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A.
The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease. |
doi_str_mv | 10.1164/rccm.200706-963OC |
format | Article |
fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2176116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17916807</sourcerecordid><originalsourceid>FETCH-LOGICAL-h285c-560be7942cbb08abd68029384e2c4b3edc953fe31293bd162bd86305097803de3</originalsourceid><addsrcrecordid>eNpVkUlLBDEQhYMo7j_Ai_RF8NKarZPORZDBDQQHccRbqKQz05F0tyQ9iv_eiON2StWrrx7FC0IHBJ8QIvhptLY7oRhLLEol2N1kDW2TilUlVxKv5xpLVnKunrbQTkrPGBNaE7yJtohURNRYbiP7CNGDCa6YxiGNsAjQN74vLmhx75LPSm9dkYVLb-JgAqQxFfM4dMUURu_63L35sS1maQmhuOlHF9PoR5-bae-W3dB72EMbcwjJ7a_eXTS7vHiYXJe3d1c3k_PbsqV1ZctKYOOk4tQag2swTb6QKlZzRy03zDVWVWzuGMmiaYigpqkFwxVWssascWwXnX35vixNl_F8XYSgX6LvIL7rAbz-P-l9qxfDq6ZEihxoNjj8a_Cz-R1XBo5WACQLYR5zOj79ckpVvMI8c8dfXOsX7ZuPTqcOQsi2RMPz57cRKTXRQrAPhbmLDQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</title><source>MEDLINE</source><source>American Thoracic Society (ATS) Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Huang, Steven K ; Wettlaufer, Scott H ; Hogaboam, Cory M ; Flaherty, Kevin R ; Martinez, Fernando J ; Myers, Jeffrey L ; Colby, Thomas V ; Travis, William D ; Toews, Galen B ; Peters-Golden, Marc</creator><creatorcontrib>Huang, Steven K ; Wettlaufer, Scott H ; Hogaboam, Cory M ; Flaherty, Kevin R ; Martinez, Fernando J ; Myers, Jeffrey L ; Colby, Thomas V ; Travis, William D ; Toews, Galen B ; Peters-Golden, Marc</creatorcontrib><description>Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator.
To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts.
Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined.
Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A.
The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/rccm.200706-963OC</identifier><identifier>PMID: 17916807</identifier><language>eng</language><publisher>New York, NY: Am Thoracic Soc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Cell Division - drug effects ; Cell Line ; Clinical death. Palliative care. Organ gift and preservation ; Collagen Type I - metabolism ; Cyclic AMP - metabolism ; Dinoprostone - pharmacology ; Drug Resistance ; E. Interstitial Lung Disease ; Female ; Fibroblasts - drug effects ; Fibroblasts - pathology ; Humans ; Intensive care medicine ; Lung - pathology ; Lung Diseases, Interstitial - pathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pulmonary Fibrosis - pathology</subject><ispartof>American journal of respiratory and critical care medicine, 2008-01, Vol.177 (1), p.66-74</ispartof><rights>2008 INIST-CNRS</rights><rights>Copyright © 2008, American Thoracic Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,4012,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19954504$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17916807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Steven K</creatorcontrib><creatorcontrib>Wettlaufer, Scott H</creatorcontrib><creatorcontrib>Hogaboam, Cory M</creatorcontrib><creatorcontrib>Flaherty, Kevin R</creatorcontrib><creatorcontrib>Martinez, Fernando J</creatorcontrib><creatorcontrib>Myers, Jeffrey L</creatorcontrib><creatorcontrib>Colby, Thomas V</creatorcontrib><creatorcontrib>Travis, William D</creatorcontrib><creatorcontrib>Toews, Galen B</creatorcontrib><creatorcontrib>Peters-Golden, Marc</creatorcontrib><title>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator.
To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts.
Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined.
Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A.
The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Division - drug effects</subject><subject>Cell Line</subject><subject>Clinical death. Palliative care. Organ gift and preservation</subject><subject>Collagen Type I - metabolism</subject><subject>Cyclic AMP - metabolism</subject><subject>Dinoprostone - pharmacology</subject><subject>Drug Resistance</subject><subject>E. Interstitial Lung Disease</subject><subject>Female</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - pathology</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Lung - pathology</subject><subject>Lung Diseases, Interstitial - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary Fibrosis - pathology</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUlLBDEQhYMo7j_Ai_RF8NKarZPORZDBDQQHccRbqKQz05F0tyQ9iv_eiON2StWrrx7FC0IHBJ8QIvhptLY7oRhLLEol2N1kDW2TilUlVxKv5xpLVnKunrbQTkrPGBNaE7yJtohURNRYbiP7CNGDCa6YxiGNsAjQN74vLmhx75LPSm9dkYVLb-JgAqQxFfM4dMUURu_63L35sS1maQmhuOlHF9PoR5-bae-W3dB72EMbcwjJ7a_eXTS7vHiYXJe3d1c3k_PbsqV1ZctKYOOk4tQag2swTb6QKlZzRy03zDVWVWzuGMmiaYigpqkFwxVWssascWwXnX35vixNl_F8XYSgX6LvIL7rAbz-P-l9qxfDq6ZEihxoNjj8a_Cz-R1XBo5WACQLYR5zOj79ckpVvMI8c8dfXOsX7ZuPTqcOQsi2RMPz57cRKTXRQrAPhbmLDQ</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Huang, Steven K</creator><creator>Wettlaufer, Scott H</creator><creator>Hogaboam, Cory M</creator><creator>Flaherty, Kevin R</creator><creator>Martinez, Fernando J</creator><creator>Myers, Jeffrey L</creator><creator>Colby, Thomas V</creator><creator>Travis, William D</creator><creator>Toews, Galen B</creator><creator>Peters-Golden, Marc</creator><general>Am Thoracic Soc</general><general>American Lung Association</general><general>American Thoracic Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20080101</creationdate><title>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</title><author>Huang, Steven K ; Wettlaufer, Scott H ; Hogaboam, Cory M ; Flaherty, Kevin R ; Martinez, Fernando J ; Myers, Jeffrey L ; Colby, Thomas V ; Travis, William D ; Toews, Galen B ; Peters-Golden, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h285c-560be7942cbb08abd68029384e2c4b3edc953fe31293bd162bd86305097803de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Division - drug effects</topic><topic>Cell Line</topic><topic>Clinical death. Palliative care. Organ gift and preservation</topic><topic>Collagen Type I - metabolism</topic><topic>Cyclic AMP - metabolism</topic><topic>Dinoprostone - pharmacology</topic><topic>Drug Resistance</topic><topic>E. Interstitial Lung Disease</topic><topic>Female</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - pathology</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Lung - pathology</topic><topic>Lung Diseases, Interstitial - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary Fibrosis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Steven K</creatorcontrib><creatorcontrib>Wettlaufer, Scott H</creatorcontrib><creatorcontrib>Hogaboam, Cory M</creatorcontrib><creatorcontrib>Flaherty, Kevin R</creatorcontrib><creatorcontrib>Martinez, Fernando J</creatorcontrib><creatorcontrib>Myers, Jeffrey L</creatorcontrib><creatorcontrib>Colby, Thomas V</creatorcontrib><creatorcontrib>Travis, William D</creatorcontrib><creatorcontrib>Toews, Galen B</creatorcontrib><creatorcontrib>Peters-Golden, Marc</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Steven K</au><au>Wettlaufer, Scott H</au><au>Hogaboam, Cory M</au><au>Flaherty, Kevin R</au><au>Martinez, Fernando J</au><au>Myers, Jeffrey L</au><au>Colby, Thomas V</au><au>Travis, William D</au><au>Toews, Galen B</au><au>Peters-Golden, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>177</volume><issue>1</issue><spage>66</spage><epage>74</epage><pages>66-74</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator.
To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts.
Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined.
Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A.
The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.</abstract><cop>New York, NY</cop><pub>Am Thoracic Soc</pub><pmid>17916807</pmid><doi>10.1164/rccm.200706-963OC</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1073-449X |
ispartof | American journal of respiratory and critical care medicine, 2008-01, Vol.177 (1), p.66-74 |
issn | 1073-449X 1535-4970 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2176116 |
source | MEDLINE; American Thoracic Society (ATS) Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete |
subjects | Adult Aged Aged, 80 and over Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Cell Division - drug effects Cell Line Clinical death. Palliative care. Organ gift and preservation Collagen Type I - metabolism Cyclic AMP - metabolism Dinoprostone - pharmacology Drug Resistance E. Interstitial Lung Disease Female Fibroblasts - drug effects Fibroblasts - pathology Humans Intensive care medicine Lung - pathology Lung Diseases, Interstitial - pathology Male Medical sciences Middle Aged Pharmacology. Drug treatments Pulmonary Fibrosis - pathology |
title | Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A00%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Variable%20Prostaglandin%20E2%20Resistance%20in%20Fibroblasts%20from%20Patients%20with%20Usual%20Interstitial%20Pneumonia&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Huang,%20Steven%20K&rft.date=2008-01-01&rft.volume=177&rft.issue=1&rft.spage=66&rft.epage=74&rft.pages=66-74&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/rccm.200706-963OC&rft_dat=%3Cpubmed_pasca%3E17916807%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17916807&rfr_iscdi=true |